Drug Trial Radar · NCT04539041
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy
Last checked: Nov 19, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
59
Actual
Start
Feb 16, 2021
Primary completion
Oct 17, 2024
Study completion Oct 17, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1, multi-center, double-blind, placebo-controlled, multiple dose escalation study with NIO752 in progressive supranuclear palsy (PSP) participants.
Conditions
- Progressive Supranuclear Palsy (PSP)
Interventions
antisense oligonucleotideDrug
solution of antisense oligonucleotide injected intrathecally (spine tap) at multiple dose levels
placeboDrug
placebo for each dose level
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of adverse events and serious adverse eventsTime frame: Baseline up to approximately one year (3-month treatment plus 9-month follow-up or 9-month treatment plus 3-month follow-up)
- Change in severity scores for Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Baseline up to approximately 1 year (3-month treatment plus 9-month follow-up or 9-month treatment plus 3-month follow-up)
- Levels of infection indicators in Cerebrospinal fluid (CSF)Time frame: Baseline up to approximately 1 year (3-month treatment plus 9-month follow-up or 9-month treatment plus 3-month follow-up)
Locations
12 sites in 4 countries. Site status is shown where the registry gives one.
University of California San Diego
La Jolla, California
Mayo Clinic Rochester
Rochester, Minnesota
Vanderbilt University Medical CenterX
Nashville, Tennessee
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Düsseldorf, Germany
Novartis Investigative Site
Hanover, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
Tübingen, Germany
Novartis Investigative Site
Ulm, Germany
Novartis Investigative Site
Bonn, North Rhine-Westphalia, Germany
Novartis Investigative Site
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.